EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

TAOK1 promotes filament formation in HR repair through phosphorylating USP7

Tian-Chen Zhu iD, Zhang-Ping He, Shu-Ting Li, Lin Zheng, Xue-Yi Zheng, Xia-Lu Lan, Chun-Hua Qu, Run-Cong Nie, Chao Gu, Li-Ning Huang, Xiao-Xia Cai, Zhi-Cheng Xiang und 2 weitere

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2422262122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Tian-Chen Zhu und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center f…. Hauptthemen laut MEDLINE: Ubiquitin-Specific Peptidase 7, Recombinational DNA Repair, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOST | National Natural Science Foundation of China (NSFC), China Postdoctoral Science Foundation (China Postdoctoral Foundation Project).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly-ADP-ribose polymerase (PARP) inhibitors are vital therapeutic agents that exploit synthetic lethality, particularly effective in tumors with homologous recombination (HR) defects. However, broadening their clinical utility remains a significant challenge. In this study, we conducted a high-throughput kinase inhibitor screen to identify potential targets exhibiting synthetical lethality with PARP inhibitors. Our results show that thousand and one amino acid protein kinase 1 (TAOK1) plays a pivotal role in the DNA damage response by phosphorylating ubiquitin specific peptidase 7 (USP7), thereby promoting its enzymatic activity and preventing the ubiquitylation and subsequent degradation of RAD51, a crucial protein in the filament formation of HR repair. Notably, genetic depletion or pharmacological inhibition of TAOK1, as well as blocking peptide targeting the USP7 phosphorylation site, impaired USP7 function, leading to RAD51 degradation, disruption of HR repair, and increased tumor cell and sensitivity to PARP inhibition. This study highlights TAOK1 as a critical regulator of HR repair pathway in human cancer cells and presents a therapeutic strategy overcoming resistance to PARPi inhibitors. These findings support the potential clinical application of combining PARP inhibitors with TAOK1 inhibition or peptide treatment to improve therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Specific Peptidase 7Recombinational DNA RepairProtein Serine-Threonine KinasesHumansRad51 RecombinasePhosphorylationCell Line, TumorPoly(ADP-ribose) Polymerase InhibitorsDNA DamageUbiquitination

Stichwörter der Autor:innen

PARP inhibitorTAOK1bladder cancerhomologous recombinationsynthetic lethality

Substanzen

Ubiquitin-Specific Peptidase 7USP7 protein, humanRad51 RecombinaseRAD51 protein, humanPoly(ADP-ribose) Polymerase InhibitorsProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou 510000, Chi…
  • Department of Pathology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510000, China.
  • Institute of Basic Medical Sciences, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 510000, China.
  • Department of Pathology and Institute of Oncology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350000, China.
  • Department of Gastric Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510000, China.
  • Department of General Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou 215000, China.

ORCID-Profile: Tian-Chen Zhu, Mu-Yan Cai

Förderung

  • MOST | National Key Research and Development Program of China (NKPs)
  • MOST | National Natural Science Foundation of China (NSFC)
  • China Postdoctoral Science Foundation (China Postdoctoral Foundation Project)
  • GDSTC | Science and Technology Planning Project of Guangdong Province (S&T Project of Guangdong Province)
  • GDSTC | Basic and Applied Basic Research Foundation of Guangdong Province ()

Zitieren

APA

Zhu, T. C., He, Z. P., Li, S. T., Zheng, L., Zheng, X. Y., Lan, X. L., Qu, C. H., Nie, R. C., Gu, C., Huang, L. N., Cai, X. X., Xiang, Z. C., Xie, D., & Cai, M. Y. (2025). TAOK1 promotes filament formation in HR repair through phosphorylating USP7. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2422262122

Vancouver

Zhu TC, He ZP, Li ST, Zheng L, Zheng XY, Lan XL, et al. TAOK1 promotes filament formation in HR repair through phosphorylating USP7. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2422262122

BibTeX
@article{Zhu2025,
  author = {Zhu, Tian-Chen and He, Zhang-Ping and Li, Shu-Ting and Zheng, Lin and Zheng, Xue-Yi and Lan, Xia-Lu and Qu, Chun-Hua and Nie, Run-Cong and Gu, Chao and Huang, Li-Ning and Cai, Xiao-Xia and Xiang, Zhi-Cheng and Xie, Dan and Cai, Mu-Yan},
  title = {TAOK1 promotes filament formation in HR repair through phosphorylating USP7},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2422262122}
}
Kostenlos starten →